Nextage Therapeutics (Israel) Analysis
| MCTC Stock | ILA 71.90 2.00 2.71% |
Nextage Therapeutics is overvalued with Real Value of 59.22 and Hype Value of 71.9. The main objective of Nextage Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Nextage Therapeutics is worth, separate from its market price. There are two main types of Nextage Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Nextage Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Nextage Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Nextage Therapeutics stock is traded in Israel on Tel Aviv Stock Exchange, with the market opening at 09:00:00 and closing at 17:30:00 every Mon,Tue,Wed,Thu,Sun except for officially observed holidays in Israel. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Nextage Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Nextage |
Nextage Stock Analysis Notes
About 22.0% of the company outstanding shares are owned by corporate insiders. The book value of Nextage Therapeutics was now reported as 0.9. The company recorded a loss per share of 0.24. Nextage Therapeutics had 1:20 split on the 12th of April 2020. Micromedic Technologies Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. Further, the company provides diagnostic solutions for multiple cancer diagnostic applications. MICROMEDIC TECHNOL operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. To find out more about Nextage Therapeutics contact Meir Yoeli at 972 73 2753450 or learn more at http://www.m-medic.com.Nextage Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Nextage Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Nextage Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Nextage Therapeutics had very high historical volatility over the last 90 days | |
| The company has 0.0 in debt which may indicate that it relies heavily on debt financing | |
| The company has a current ratio of 0.43, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Nextage Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Nextage Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nextage Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nextage to invest in growth at high rates of return. When we think about Nextage Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Nextage Therapeutics reported the revenue of 297 K. Net Loss for the year was (2.09 M) with profit before overhead, payroll, taxes, and interest of 207 K. | |
| Nextage Therapeutics has accumulated about 358 K in cash with (5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.16. | |
| Roughly 22.0% of the company outstanding shares are owned by corporate insiders |
Nextage Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.54 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nextage Therapeutics's market, we take the total number of its shares issued and multiply it by Nextage Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Nextage Profitablity
Nextage Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Nextage Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Nextage Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Nextage Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Nextage Therapeutics' profitability requires more research than a typical breakdown of Nextage Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (2.3) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (9.71) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $9.71. Technical Drivers
As of the 27th of November, Nextage Therapeutics secures the Mean Deviation of 4.13, risk adjusted performance of 0.0344, and Downside Deviation of 5.15. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nextage Therapeutics, as well as the relationship between them.Nextage Therapeutics Price Movement Analysis
The output start index for this execution was three with a total number of output elements of fifty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Nextage Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Nextage Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Nextage Therapeutics Outstanding Bonds
Nextage Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Nextage Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Nextage bonds can be classified according to their maturity, which is the date when Nextage Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Nextage Therapeutics Predictive Daily Indicators
Nextage Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Nextage Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Nextage Therapeutics Forecast Models
Nextage Therapeutics' time-series forecasting models are one of many Nextage Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Nextage Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Nextage Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Nextage Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Nextage shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Nextage Therapeutics. By using and applying Nextage Stock analysis, traders can create a robust methodology for identifying Nextage entry and exit points for their positions.
Micromedic Technologies Ltd develops and commercializes in-vitro cancer diagnostic products and solutions worldwide. Further, the company provides diagnostic solutions for multiple cancer diagnostic applications. MICROMEDIC TECHNOL operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Nextage Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Idea Analyzer Now
Idea AnalyzerAnalyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
| All Next | Launch Module |
Complementary Tools for Nextage Stock analysis
When running Nextage Therapeutics' price analysis, check to measure Nextage Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nextage Therapeutics is operating at the current time. Most of Nextage Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nextage Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nextage Therapeutics' price. Additionally, you may evaluate how the addition of Nextage Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |